Close

Prothena Corp. (PRTA) to Discuss Phase 2 Development Strategy in Psoriatic Arthritis for PRX003

September 29, 2016 4:07 PM EDT Send to a Friend
Prothena Corporation plc (Nasdaq: PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login